Unlocking data silos using Federated Computing (FC) has the potential to achieve a positive impact across the healthcare industry, ranging from clinical care quality improvement and accreditation to population health management, precision public health…
Continue Reading
In 2018, long before the artificial intelligence (AI) bandwagon started careening down the mainstream, DeepMind, a subsidiary of Google parent Alphabet, developed a program named AlphaFold to predict protein structures faster and more accurately…
Continue Reading
The Future of Medicine: AI’s Journey in Healthcare?
Shaping the future of healthcare with the most recent technological advancements
“The Future of Medicine: AI’s Journey in Healthcare” is an exclusive eBook that explores the transformative impact…
Drug development has always been and remains expensive. Estimates are conflicting. The long cited number to bring a drug to maret has been 3 billion US dollars. A 2020 study corrected that estimate to…
Continue Reading
Digital health technologies (DHTs) enable remote data collection, support a patient-centric approach to drug development, and provide real-time data in real-world settings. With increasing use of DHTs in clinical care and development, we expect…
Continue Reading
The imperative to enhance access to quality care and research is a central concern gripping both the healthcare and pharmaceutical sectors. At the heart of this challenge lies the crucial necessity for clean and…
Continue Reading
Healthcare innovation in drug development intersects with a few critical trends: the rise of artificial intelligence (AI) applications in healthcare—particularly machine learning (ML) and predictive analytics; the need to reduce the costs associated with…
Continue Reading
According to a report, 90% of futurists predict widespread usage of digital twins within a decade, revolutionizing healthcare. Digital twins are virtual models that aid in personalized treatment plans, predicting health outcomes, and drug…
Continue Reading
As of April 2023, the number of recruiting studies in the US was 24,138. Based on FDA data from new drug approvals in 2021, we can assume an average of 760 patients are needed…
Continue Reading
A whole new way to develop medicines has grown up around biotherapeutics, of which the best-known are a subset called biosimilars. Over the past ten years, a class of biotherapeutics called cell and gene…
Continue Reading
